acetyl-CoA acetyltransferase 1Genealiases: ACAT · MAT · T2 · THIL
Q-omics provides the consensus-scored ACAT1 profile across patient tissues and cancer cell-line models. ACAT1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACAT1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ACAT1 protein abundance shows 21,865 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where ACAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACAT1 survival associations across molecular data types. ACAT1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACAT1 RNA expression–survival associations across cancer types. High ACAT1 expression shows unfavorable associations in BLCA and CESC, but favorable associations in KIRC, KIRP, LIHC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACAT1 RNA expression.
This table summarizes ACAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACAT1 shows lower tumor expression in COAD, KIRP, THCA, BLCA, KIRC and LIHC. The COAD box plot shows higher ACAT1 RNA expression in normal versus tumor tissue (log2 FC = −1.374, t-test p < 0.001).
This table shows molecular features associated with ACAT1 in patient tissues and cancer cell lines. In patient samples, ACAT1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and PANCREAS.
